A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Tislelizumab，200 mg, iv, d1, Q3W, until disease progression or intolerable toxicity."

"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Anlotinib 12mg QD po d1-14，Q3W,until disease progression or intolerable toxicity."